Related Experiment Video
Updated: Jul 16, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic
Yamato Numata1, Go Kimura1, Jun Akatsuka1
1Department of Urology Nippon Medical School Tokyo Japan.
Introduction:
The combination of enzalutamide and radium-223 has demonstrated clinical efficacy in metastatic castration-resistant prostate cancer; however, real-world evidence remains limited, particularly with PSA-discordant progression.
Case Presentation:
A 74-year-old man with high-risk localized prostate cancer was treated with androgen deprivation therapy followed by definitive external beam radiotherapy. Eight months later, the disease progressed radiographically with extensive bone, nodal, and solitary liver metastases, while prostate-specific antigen levels remained persistently low, consistent with prostate-specific antigen-discordant progression. Bone turnover markers and disease activity markers were markedly elevated. Combination therapy with enzalutamide and radium-223 was initiated, and six cycles of radium-223 were completed. Following treatment, skeletal disease activity and bone turnover markers improved markedly. Apart from grade 3 anemia requiring transfusion, no severe adverse events occurred.
Conclusion:
This case suggests that enzalutamide combined with radium-223 may provide clinical benefit in metastatic castration-resistant prostate cancer with PSA-discordant progression.
